Prostate cancer-derived holoclones: a novel and effective model for evaluating cancer stemness

Prostate cancer accounts for approximately 13.5% of all newly diagnosed male cancer cases. Significant clinical burdens remain in terms of ineffective prognostication, with overtreatment of insignificant disease. Additionally, the pathobiology underlying disease heterogeneity remains poorly understo...

Descripción completa

Detalles Bibliográficos
Autores principales: Flynn, Louise, Barr, Martin P., Baird, Anne-Marie, Smyth, Paul, Casey, Orla M., Blackshields, Gordon, Greene, John, Pennington, Stephen R., Hams, Emily, Fallon, Padraic G., O’Leary, John, Sheils, Orla, Finn, Stephen P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347552/
https://www.ncbi.nlm.nih.gov/pubmed/32647229
http://dx.doi.org/10.1038/s41598-020-68187-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347552/
https://www.ncbi.nlm.nih.gov/pubmed/32647229
http://dx.doi.org/10.1038/s41598-020-68187-9

Ejemplares similares